2026 Corporate Membership Prospectus Available

• The 2026 Corporate Membership Application will open Friday, September 19th
• Companies on the 2025 waitlist will be sent a registration code with additional instructions on Wednesday, September 17th.
• All other companies will be eligible to apply for the 2026 Corporate Membership Lottery

2026 Corporate Membership Application

• My company has a 2025 corporate membership - do I need to sign up for the lottery? YES!
• Are current members guaranteed a spot for next year? NO - if we did this, other companies wouldn't get a chance to participate. There are nearly 90 companies who have in the past participated or expressed interest in participating with NNECOS. 
• I applied for 2025 corporate membership last fall, but didn't get a spot for 2025 was on the official waitlist. Can I apply for 2026 membership early? YES! A code will be emailed to your company primary contact on Wednesday, 9/17 to participate in the first round application - please email info@nnecos.org if you need assistance.
• I'm not currently a member and I wasn't on the waitlist from 2025 - what do I need to do to apply? Sign up for the lottery no later than Monday, 9/22.
• When will the lottery be drawn? Tuesday, 9/23
• Is everyone in the lottery guaranteed a spot - no - the lottery determines the order in which you are able to apply for remaining spots. 
• What if I'm in the lottery but don't get a spot - you will be on the waitlist and eligible to apply in the first round next year.

• 2025 Waitlist Companies will be sent a code via email on Wednesday, September 17th
• Companies who apply for the 2026 Corporate Membership Lottery by September 22nd will be part of the lottery drawn on September 23rd.
• Companies who miss the lottery sign-up may sign up for the 2026 Corporate Member Post-Lottery Wait List through October 31, 2025. After October 31st, the 2026 application process will be closed. 

System note - the website has AGGRESSIVE COOKIES, so if you tried signing up for a level but were supposed to sign-up for the waitlist, you may not be able to access the waitlist "ticket." Please try an incognito browser. 

2026 Waitlist & Lottery Process
If a membership level is sold out, waitlist requests will be accepted for 2026. All lottery participants who are not able to apply will also be placed on the 2026 waitlist.

Note: The lottery determines the order of application, not membership availability. Every company that enters will receive a lottery number, but because we anticipate more applicants than available memberships, a lottery number does not guarantee a membership opportunity at the time of selection.

We strongly recommend securing an available corporate membership level, as the availability of a level from the waitlist cannot be guaranteed. The form includes an opportunity to request an upgrade should one become available. 

Documentation of membership approval by your company, including the commitment to pay the membership dues, is required within 30 days of receipt of the necessary documentation. Non-verified requests will be released and made available to the next company on the waitlist.

(Example: Company ABC is approved for Gold Corporate membership on 9/23/25. NNECOS provides the requested documentation on 9/25/25. Company ABC is required to provide documentation of membership approval/commitment to pay membership dues no later than 10/25/25, with an explicit timeline for receipt of payment - no later than 1/31/26. Without this documentation, the spot will be made available to another company).

The board has also designated 25% of available membership opportunities for non-pharmaceutical companies (testing, equipment, software, radiation oncology, etc.). Any opportunities remaining 90 days before the annual meeting will be made available without restriction by company type. Corporate membership dues are non-refundable, paid on an annual basis, and can not be pro-rated. 

Please review all levels/benefits carefully.

Primary Contact List

AADI

Agios

Alexion Pharmaceuticals

Amgen

BioLine Rx

Blueprint Medicines

Boehringer-Ingelheim

Deciphera Pharmaceuticals

Eisai

EMD Serono

Genentech

Incyte

Janssen Biotech/J&J

Jazz Pharmaceuticals

Kite Pharma

Legend Biotech

Pfizer

Puma Biotechnology

Springworks Therapeutics

Sumitomo Pharma

Taiho Oncology

Current W9 - January 2025